- Home
- PCYO vs SLP Comparison
PCYO vs SLP Comparison
Compare PCYO & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- SLP
- Stock Information
- Founded
- PCYO 1976
- SLP 1996
- Country
- PCYO United States
- SLP United States
- Employees
- PCYO N/A
- SLP N/A
- Industry
- PCYO Water Supply
- SLP EDP Services
- Sector
- PCYO Utilities
- SLP Technology
- Exchange
- PCYO Nasdaq
- SLP Nasdaq
- Market Cap
- PCYO 267.7M
- SLP 282.4M
- IPO Year
- PCYO N/A
- SLP 1997
- Fundamental
- Price
- PCYO $11.56
- SLP $16.06
- Analyst Decision
- PCYO
- SLP Buy
- Analyst Count
- PCYO 0
- SLP 7
- Target Price
- PCYO N/A
- SLP $29.50
- AVG Volume (30 Days)
- PCYO 36.4K
- SLP 445.5K
- Earning Date
- PCYO 11-12-2025
- SLP 10-22-2025
- Dividend Yield
- PCYO N/A
- SLP N/A
- EPS Growth
- PCYO 123.89
- SLP N/A
- EPS
- PCYO 0.56
- SLP N/A
- Revenue
- PCYO $27,447,000.00
- SLP $80,383,000.00
- Revenue This Year
- PCYO N/A
- SLP $12.75
- Revenue Next Year
- PCYO N/A
- SLP $3.06
- P/E Ratio
- PCYO $19.99
- SLP N/A
- Revenue Growth
- PCYO 40.36
- SLP 20.01
- 52 Week Low
- PCYO $9.65
- SLP $12.39
- 52 Week High
- PCYO $14.63
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- PCYO 70.43
- SLP 65.42
- Support Level
- PCYO $10.80
- SLP $13.78
- Resistance Level
- PCYO $11.64
- SLP $16.27
- Average True Range (ATR)
- PCYO 0.33
- SLP 0.65
- MACD
- PCYO 0.09
- SLP 0.23
- Stochastic Oscillator
- PCYO 95.73
- SLP 91.14
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.